Drug Trial Radar · NCT00383708
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
Last checked: Nov 20, 2026Latest source record: Sep 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Oct 2006
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.
Conditions
- Acromegaly
Interventions
lanreotide (Autogel formulation)Drug
120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
PegvisomantDrug
Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration PeriodTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)
- Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Previous Treatment and by Final Dose of PegvisomantTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)
- Percentage of Subjects With Acromegaly With a Normalised (Age and Sex Adjusted) IGF-1 Level at the End of the Co-administration Period; Summarised by Diabetic Status at BaselineTime frame: V3 (Week 12; Baseline) up to V11 (Week 44)
Locations
24 sites in 10 countries. Site status is shown where the registry gives one.
University Hospital, Charles University
Hradec Králové, Czechia
Charles University
Prague, Czechia
Aarhus Kommunehospital
Aarhus, Denmark
Groupe Hospitalier Henri Mondor- Albert Chenevier
Créteil, France
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Clinique Marc Linquette
Lille, France
Hôpital de la Timone
Marseille, France
CHU de Rangueil
Toulouse, France
Charite Campus Mitte
Berlin, Germany
Klinikum Johann Wolfgang Goethe-Universität
Frankfurt, Germany
Medizinische Klinik Innenstadt
München, Germany
Anticancer Hospital Metaxa Piraeus
Piraeus, Greece
Universitá degli Studi di Milano
Milan, Italy
University Federico II
Naples, Italy
Universitá di Torino
Torino, Italy
Leiden University Medical Center
Leiden, Netherlands
Dept. of Internal Medicine Erasmus MC
Rotterdam, Netherlands
Hospital General de Alicante
Alicante, Spain
Clínica Puerta de Hierro
Madrid, Spain
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, Spain
Sahlgrenska University Hospital
Gothenburg, Sweden
Uppsala University Hospital
Uppsala, Sweden
Christie Hospital and Holt Radium Institute
Manchester, United Kingdom
Royal Hallamshire Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.